Fever is a common side effect of many vaccinations; an estimated one-third of people receiving Pfizer's Prevnar 13 develop a mild case. Flu vaccines also cause cases, prompting researchers to investigate a question--does giving the shots simultaneously raise the risk of fever? The resulting study suggests the answer is yes.
Foreign drugmakers have had their fair share of struggles in China this year as the country looked to cut down on healthcare spending and root out bribery. But neither of those factors caused a Tuesday holdup of a Pfizer drug. Instead, the company is blaming a paperwork problem for an import suspension on antifungal drug Diflucan.
When Pfizer unveiled plans to carve up the business into three units, the company's top lawyer Amy Schulman was one of the big winners. Schulman was to take charge of a new unit that combined the vaccine, cancer and consumer products businesses. Now, two weeks before Schulman was due to start in the role, she is out of a job.
After years of wrangling over Pfizer's patent on Viagra, Teva Pharmaceutical Industries has made a deal. Under an agreement with Pfizer, the Israeli generics giant can launch its version of the blockbuster pill on Dec. 11, 2017, more than two years before its final patent protection expires.
As recently as last Thursday, Pfizer's Amy Schulman was fully expecting to move into a new and better job at Pfizer on Jan. 1. By Tuesday, she was out of a job altogether. So writes Fortune' s Patricia Sellers, who lunched with Schulman last week in New York.
In July, Amy Schulman looked to be one of the most powerful women in Big Pharma. As part of CEO Ian Read's plan to split Pfizer's internal operations into three distinct units, he tapped Schulman to lead the company's vaccines, oncology and consumer healthcare business. Now, Schulman is out.
Siemens will concoct diagnostic tests for some Pfizer drugs, the German conglomerate has disclosed. As is the norm with these type of deals, neither side is releasing financial details.
The huge sales generated by Prevnar 13 mean Pfizer appears to have the pneumococcal vaccine sector sewn up, but Genocea Biosciences sees an opportunity to disrupt the monopoly. This week, the biotech began a Phase I clinical trial of the vaccine it thinks can unseat Prevnar.
It was March 2010 when Pfizer first lost its bid to escape a $142 million racketeering verdict, with a federal jury ruling the company's marketing of epilepsy treatment Neurontin violated both federal and state law. Now, nearly four years later, Pfizer's appeal process has come to the end of the line. The Supreme Court has refused to hear the drugmaker's appeal, leaving the verdict intact and the door open for similar claims to proceed.
Pfizer has joined the list of Big Pharmas caving to public pressure and opening up their data vaults, and that could mean a valuable trove of study results for CROs plotting new trials--assuming the drugmaker feels like sharing.